Read our insights on what’s happening in the industry today.
Making sure CROs are prepared for the next iteration of ICH regulations was the topic of a recent webinar sponsored by Oracle. The expert panel featured FHI Clinical’s own Rob King, Chief Operating Officer, alongside executives from other organizations.
Results of recent studies that we supported focusing on vaccination against Streptococcus pneumoniae, a Gram-positive bacterium that is responsible for the majority of community-acquired pneumonia, were recently published, providing more evidence for health departments to use when developing their pediatric vaccination strategies.
Expert panelists from the FHI Clinical roundtable at the Vitual Global Forum on TB Vaccines conference shared their thoughts on the new WHO guidelines for TPT and the implications for TB vaccine development. See what they had to say here.
The Colors of COVID Town Hall Event: The Ethical Engagement of Minority Communities in COVID Clinical Research
In April, the Director of the Maryland Center for Health Equity’s Dr. Stephen B. Thomas partnered with FHI Clinical for a frank conversation by experts about COVID and how to encourage Brown and Black communities to participate in clinical research.
Michelle Atallah, Director, Business Development, discusses how FHI Clinical quickly adopted new ways to enable fully remote site monitoring in some of our ongoing studies.
FHI Clinical continues to work with researchers to identify and initiate global sites with the most appropriate capabilities and patient population for study-specific protocols. While the COVID-19 pandemic and its aftermath have presented unique challenges this past year, there are many lessons learned that we can apply to all of our future studies for a larger impact and gained efficiencies.
A question I often hear is, “What are you most looking forward to after lockdown?” My answer relates to something that happened just as the pandemic was taking off in the United States last year: FHI Clinical was awarded the oversight of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Network and had to recruit, hire and train over 200 staff in Liberia to manage the PREVAIL work. Due to travel restrictions and the unknown risks of COVID, we had to do this remotely.